Rashmi K. Murthy
About
Rashmi K. Murthy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging.
According to data from OpenAlex, Rashmi K. Murthy has authored 85 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 36 papers in Pulmonary and Respiratory Medicine and 27 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Rashmi K. Murthy's work include HER2/EGFR in Cancer Research (41 papers), Advanced Breast Cancer Therapies (23 papers) and Cancer Treatment and Pharmacology (23 papers). Rashmi K. Murthy is often cited by papers focused on HER2/EGFR in Cancer Research (41 papers), Advanced Breast Cancer Therapies (23 papers) and Cancer Treatment and Pharmacology (23 papers). Rashmi K. Murthy collaborates with scholars based in United States, Germany and United Kingdom. Rashmi K. Murthy's co-authors include Ian E. Krop, Shanu Modi, Shunji Takahashi, Junji Tsurutani, Charles H. Redfern, Yasuaki Sagara, Caleb Lee, Toshihiko Doi, Hiroji Iwata and Javad Shahidi and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.
In The Last Decade
Rashmi K. Murthy
81 papers receiving 2.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Rashmi K. Murthy United States | 24 | 2.3k | 974 | 839 | 644 | 599 | 85 | 2.9k | ||
| Philippe Aftimos Belgium | 25 | 1.9k 0.8× | 809 0.8× | 690 0.8× | 934 1.5× | 785 1.3× | 144 | 3.1k | ||
| Kevin Kalinsky United States | 30 | 2.1k 0.9× | 994 1.0× | 559 0.7× | 853 1.3× | 728 1.2× | 150 | 3.1k | ||
| Komal Jhaveri United States | 29 | 1.8k 0.8× | 1.2k 1.2× | 888 1.1× | 627 1.0× | 639 1.1× | 173 | 2.9k | ||
| Giancarlo Bisagni Italy | 25 | 1.9k 0.9× | 832 0.9× | 918 1.1× | 570 0.9× | 747 1.2× | 127 | 2.9k | ||
| Adam Knott United Kingdom | 17 | 3.2k 1.4× | 984 1.0× | 1.4k 1.7× | 843 1.3× | 1.0k 1.7× | 33 | 4.2k | ||
| Michael W. Lu United States | 14 | 2.9k 1.3× | 1.0k 1.0× | 1.6k 1.9× | 675 1.0× | 530 0.9× | 18 | 3.7k | ||
| Stephen D. Rubin United States | 13 | 2.6k 1.2× | 1.3k 1.4× | 811 1.0× | 1.1k 1.7× | 673 1.1× | 17 | 4.0k | ||
| Binghe Xu China | 26 | 2.4k 1.0× | 1.0k 1.0× | 482 0.6× | 666 1.0× | 1000 1.7× | 149 | 3.1k | ||
| Dimitrios Zardavas Belgium | 21 | 2.1k 0.9× | 854 0.9× | 589 0.7× | 945 1.5× | 1.3k 2.2× | 69 | 3.3k | ||
| Alvaro Moreno‐Aspitia United States | 26 | 1.9k 0.8× | 664 0.7× | 481 0.6× | 632 1.0× | 781 1.3× | 105 | 2.7k |
Countries citing papers authored by Rashmi K. Murthy
Since
Specialization
Citations
This map shows the geographic impact of Rashmi K. Murthy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rashmi K. Murthy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rashmi K. Murthy more than expected).
Fields of papers citing papers by Rashmi K. Murthy
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Rashmi K. Murthy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rashmi K. Murthy. The network helps show where Rashmi K. Murthy may publish in the future.
Co-authorship network of co-authors of Rashmi K. Murthy
This figure shows the co-authorship network connecting the top 25 collaborators of Rashmi K. Murthy. A scholar is included among the top collaborators of Rashmi K. Murthy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rashmi K. Murthy. Rashmi K. Murthy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
O’Brien, Barbara, Rashmi K. Murthy, Donald A. Berry, et al.. (2024). Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results.. Journal of Clinical Oncology. 42(16_suppl). 2018–2018.
2.
Smith, Grace L., Benjamin D. Smith, Chi‐Fang Wu, et al.. (2024). Financial toxicity in breast cancer patients receiving regional nodal irradiation: Variation by cancer subtype. The Breast. 78. 103813–103813.
3.
Faiz, Saadia A., et al.. (2024). Sleep disturbances based on patient reported outcomes in patients with breast cancer. Sleep And Breathing. 28(6). 2491–2500.
4.
Damodaran, Senthil, Diane Liu, Jill L. Schwartz, et al.. (2023). Abstract P3-02-03: A phase Ib trial of bintrafusp alfa and eribulin in patients with metastatic triple negative breast cancer (TNBC). Cancer Research. 83(5_Supplement). P3–2.
5.
Valero, Vicente, Jason Mouabbi, Rashmi K. Murthy, et al.. (2023). 132P Neoadjuvant zanidatamab for stage I node-negative HER2- positive breast cancer (BC). ESMO Open. 8(1). 101471–101471.
6.
Jérusalem, Guy, Yeon Hee Park, Sara A. Hurvitz, et al.. (2022). Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis. Cancer Discovery. 12(12). 2754–2762.
7.
Curigliano, Giuseppe, Volkmar Mueller, Virginia F. Borges, et al.. (2021). Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Annals of Oncology. 33(3). 321–329.
8.
Clifton, Guy T., Diane F. Hale, Timothy J. Vreeland, et al.. (2020). Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer. Clinical Cancer Research. 26(11). 2515–2523.
9.
Murthy, Rashmi K., Juhee Song, Akshara Singareeka Raghavendra, et al.. (2020). Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice. npj Breast Cancer. 6(1). 11–11.
10.
Tamura, Kenji, Junji Tsurutani, Shunji Takahashi, et al.. (2019). Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. The Lancet Oncology. 20(6). 816–826.
11.
Clifton, Guy T., Kaitlin M. Peace, Jarrod P. Holmes, et al.. (2019). Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors. Clinical Immunology. 201. 48–54.
12.
Murthy, Rashmi K., Virginia F. Borges, Alison Conlin, et al.. (2018). Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. The Lancet Oncology. 19(7). 880–888.
13.
Yam, Clinton, Rashmi K. Murthy, Vicente Valero, et al.. (2018). A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Investigational New Drugs. 36(2). 299–306.
14.
Fujii, Takeo, Takahiro Kogawa, Jimin Wu, et al.. (2017). Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. British Journal of Cancer. 116(4). 509–514.
15.
Diab, Adi, Cara Haymaker, Marc Uemura, et al.. (2017). A Phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma. Annals of Oncology. 28. v421–v421.
16.
Litton, Jennifer K., Rhys Williams, Pamela T. Soliman, et al.. (2017). Phase I expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancer. Annals of Oncology. 28. v130–v131.
17.
Moulder, Stacy L., Jennifer K. Litton, EA Mittendorf, et al.. (2016). Improving outcomes in triple-negative breast cancer (TNBC) using molecular characterization and diagnostic imaging to identify and treat chemo-insensitive disease. Annals of Oncology. 27. vi67–vi67.
18.
Harano, Kenichi, Xiudong Lei, Ana M. González-Angulo, et al.. (2016). Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 159(2). 367–374.
19.
Litton, Jennifer K., Marion E. Scoggins, Rashmi K. Murthy, et al.. (2016). A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation. Annals of Oncology. 27. vi46–vi46.
20.
Murthy, Rashmi K., Ankur Varma, Kenneth R. Hess, et al.. (2014). Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2‐positive metastatic breast cancer. Cancer. 120(13). 1932–1938.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Philippe Aftimos Breakdown of academic impact, for papers by Kevin Kalinsky Breakdown of academic impact, for papers by Komal Jhaveri Breakdown of academic impact, for papers by Giancarlo Bisagni Breakdown of academic impact, for papers by Adam Knott Breakdown of academic impact, for papers by Michael W. Lu Breakdown of academic impact, for papers by Stephen D. Rubin Breakdown of academic impact, for papers by Binghe Xu Breakdown of academic impact, for papers by Dimitrios Zardavas Breakdown of academic impact, for papers by Alvaro Moreno‐Aspitia